RxDoctor Payments Data

Alex Lee

Internal Medicine · East Rockaway, NYNPI 1831128214

Payments from drug & device makers

$2,047in general payments, 2019–2025

Across 48 payments — averaging $42.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$634
  • AstraZeneca$395
  • AbbVie$276
  • Lilly USA, LLC$271
  • Pfizer$240
  • Novo Nordisk$179
  • plus $52 from 2 others

What the payments were for

  • Food & beverage$2,047100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK11$634
AstraZeneca6$395
AbbVie(2 entities)8$276
Lilly USA, LLC7$271
Pfizer6$240
Novo Nordisk8$179
Boehringer Ingelheim1$30
Merck1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,047 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$242,448
Medicare patients
121
Services billed
2,625

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide29$74,822
FarxigaDapagliflozin Propanediol39$61,992
TrulicityDulaglutide27$49,304
MounjaroTirzepatide32$40,857
EliquisApixaban22$18,941
ViberziEluxadoline11$16,824
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$2,331
Metoprolol Succinate123$2,005
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen28$1,658
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide42$1,266
Levothyroxine Sodium77$1,258
Mirtazapine38$1,226
Rosuvastatin Calcium71$1,198
Atorvastatin Calcium132$1,111
Montelukast Sodium137$1,100

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$271$90,16159 claims
Novo NordiskOzempic$179$74,82229 claims
AstraZenecaFarxiga$395$61,99239 claims
PfizerEliquis$240$18,94122 claims
AbbVieViberzi$276$16,82411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in East Rockaway

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →